News

NeedleSmart PRO Receives FDA Approval

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

An innovation helping millions manage the side effects of cancer treatment

19 Dec 2024
A UK business with expertise in cooling and refrigeration has evolved to develop innovative ways to radically reduce the trauma linked to cancer treat...

DMHIC Report: Evaluating Digital Interventions for ADHD Diagnosis and Management for Adults within the UK

17 Dec 2024
Download DHI's "Evaluating Digital Interventions for ADHD Diagnosis and Management for Adults within the UK (Excluding Scotland)" here.

Strata Health Solutions Shortlisted for Best Contribution to the Improvement of Urgent and Emergency Care at the 2025 HSJ Partnership Awards

17 Dec 2024
Strata Health Solutions, NHS England, and East Lancashire Hospitals Trust are thrilled to announce that our Urgent and Emergency Care Digital Front Do...

4C Accelerator – Apply for the free qualification program for MedTech startups

12 Dec 2024
Until January 17, 2025 founders in the MedTech sector can apply for the free & funded “4C Accelerator”. The programm enables founders in the MedTe...

Future4care International Call4Applications 2025 – Now Open!

10 Dec 2024
Are you a digital health startup looking to expand into France and Germany? Don’t miss the opportunity to join Future4care’s one-year, equity-free acc...

AGE-WELL, Canada’s technology and aging network, releases its 2023-2024 Annual Report

10 Dec 2024
Hot off the digital press, the latest AGE-WELL annual report, AgeTech for Aging Well, showcases recent activities and accomplishments from across the ...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *